Abstract
Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.
Original language | English |
---|---|
Pages (from-to) | 297-301 |
Number of pages | 5 |
Journal | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi |
Volume | 46 |
Issue number | 4 |
Publication status | Published - 2005 Oct |
ASJC Scopus subject areas
- Medicine(all)